A Biophysical Therapeutic for Traumatic Brain Injury and other Battlefield Injuries

Battlefield injuries are unique in terms of severity, types, and combinations. The ability to develop therapeutics designed to treat a broad spectrum of battle injuries is a unique opportunity with significant positive benefits. In particular, increased capillary permeability/leak and ischemia-reperfusion injuries play a significant role in military injuries such as battlefield trauma, hemorrhagic shock, burns/smoke inhalation injuries, traumatic brain injury, sepsis, pulmonary edema induced by chemical/biological agents, or infectious diseases. Therapeutics for traumatic brain injury presents the most pressing unmet need on the battlefield. BioPhyZica is developing an experimental drug, BPZ-302, as a medic deliverable broad spectrum therapeutic against injuries involving capillary permeability/leak and ischemia-reperfusion injury. In a preclinical study, we have found that treatment with BPZ-302 results in statistically significant reduction in cerebral edema caused by cardiac arrest-induced global cerebral ischemia. This Phase I, will evaluate if BPZ-302 ability to reduce cerebral edema improves neurological outcomes in for military personnel with traumatic brain injuries